Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany

Diabetes, Obesity and Metabolism

Volumn 20, Issue 2, 2018, Pages 389-399

  Khunti, Kamlesh ^a   Godec, Thomas R ^b   Medina, Jesús ^c   Garcia Alvarez, Laura ^d   Hiller, Josh ^d   Gomes, Marilia B ^e   Cid Ruzafa, Javier ^f   Charbonnel, Bernard ^g   Fenici, Peter ^c   Hammar, Niklas ^h,i   Hashigami, Kiyoshi ^c   Kosiborod, Mikhail ^j,k   Nicolucci, Antonio ^l   Shestakova, Marina V ^m,n   Ji, Linong ^o   Pocock, Stuart ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d IQVIA   (United States)

^e STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f EVIDERA   (United States)

^g UNIVERSITÉ DE NANTES   (France)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^k UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^l Center for Outcomes Research and Clinical Epidemiology   (Italy)

^m ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

ⁿ I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^o PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

more..

Author keywords

glycaemic control; observational study; primary care; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; AGING; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GERMANY; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNITED KINGDOM; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG MONITORING; DRUG RESISTANCE; ELECTRONIC HEALTH RECORD; HYPERGLYCEMIA; HYPOGLYCEMIA; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; GERMANY; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; UNITED KINGDOM; YOUNG ADULT;

EID: 85030453598     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13083     Document Type: Article

References (30)

1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed.; 2015. http://www.diabetesatlas.org/. Accessed November 30, 2016.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
3. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
5. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156:218–231.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
7. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438–447.
8. International Diabetes Federation. Global guideline for type 2 diabetes. 2012. https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes.html. Accessed April 24, 2017.
9. American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(suppl 1):S1–S132.
10. Ji L, Bonnet F, Charbonnel B, et al. Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: rationale and methods of the DISCOVER observational study program. J Diabetes Complications. 2017;31(7):1188–1196.
11. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmaco-epidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47:617–626.
12. The Health Improvement Network Research Team. THIN Database. https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database. Accessed April 24, 2017.
13. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16:393–401.
14. Denburg MR, Haynes K, Shults J, Lewis JD, Leonard MB. Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2011;20:1138–1149.
15. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80 000 people. Diabetes Care. 2013;36:3411–3417.
16. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600–606.
17. Fu AZ, Qiu Y, Davies MJ, Radican L, Engel SS. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab. 2011;13:765–769.
18. Fu AZ, Sheehan JJ. Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control. Curr Med Res Opin. 2017;33:853–858.
19. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
20. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS Study. Diabetes. 2015;64:1786–1793.
21. Pongwecharak J, Tengmeesri N, Malanusorn N, Panthong M, Pawangkapin N. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci. 2009;31:481–486.
22. NICE Clinical Guidelines. The management of type 2 diabetes. 2009. https://www.nice.org.uk/guidance/ta203/resources/nice-recommends-liraglutide-for-type-2-diabetes-mellitus4. Accessed January 20, 2017.
23. Pfeiffer AF, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int. 2014;111:69–81; quiz 82.
24. Gupta V, Kalra S. Choosing a gliptin. Indian J Endocrinol Metab. 2011;15:298–308.
25. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410–1418.
26. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316:313–324.
27. Rathmann W, Bongaerts B, Kostev K. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study. Diabetes Obes Metab. 2016;18:840–843.
28. Wilding JP, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29:438–444.
29. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–1224.
30. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175–194.